SiBone (NASDAQ:SIBN) CEO Sells $522,556.64 in Stock

by · The Cerbat Gem

SiBone (NASDAQ:SIBN – Get Free Report) CEO Laura Francis sold 25,972 shares of the stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $20.12, for a total transaction of $522,556.64. Following the transaction, the chief executive officer owned 291,491 shares in the company, valued at approximately $5,864,798.92. The trade was a 8.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Laura Francis also recently made the following trade(s):

  • On Friday, August 21st, Laura Francis sold 3,923 shares of SiBone stock. The stock was sold at an average price of $20.02, for a total transaction of $78,538.46.
  • On Thursday, August 20th, Laura Francis sold 51,884 shares of SiBone stock. The stock was sold at an average price of $19.46, for a total value of $1,009,662.64.

SiBone Trading Down 0.6%

SIBN stock traded down $0.11 during trading on Wednesday, reaching $19.43. 601,112 shares of the stock traded hands, compared to its average volume of 544,512. The business’s 50 day moving average price is $17.74 and its 200-day moving average price is $15.40. SiBone has a 52-week low of $11.48 and a 52-week high of $21.89. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.15 and a quick ratio of 7.55. The firm has a market capitalization of $861.72 million, a PE ratio of -57.15 and a beta of 0.66.

SiBone (NASDAQ:SIBN – Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.06. SiBone had a negative net margin of 6.85% and a negative return on equity of 8.23%. The company had revenue of $56.01 million during the quarter, compared to analyst estimates of $55.34 million. As a group, sell-side analysts forecast that SiBone will post -0.4 earnings per share for the current year.

Hedge Funds Weigh In On SiBone

Institutional investors and hedge funds have recently modified their holdings of the stock. First Light Asset Management LLC increased its position in SiBone by 162.4% in the 4th quarter. First Light Asset Management LLC now owns 5,032,904 shares of the company’s stock worth $99,249,000 after purchasing an additional 3,115,001 shares during the last quarter. Granahan Investment Management LLC boosted its stake in shares of SiBone by 97.6% during the 1st quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company’s stock worth $21,965,000 after acquiring an additional 858,942 shares in the last quarter. California State Teachers Retirement System raised its stake in shares of SiBone by 1,751.6% in the 2nd quarter. California State Teachers Retirement System now owns 726,942 shares of the company’s stock valued at $11,864,000 after acquiring an additional 687,681 shares in the last quarter. Paradigm Capital Management Inc. NY lifted its holdings in SiBone by 113.3% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,126,500 shares of the company’s stock worth $14,228,000 after purchasing an additional 598,300 shares during the last quarter. Finally, Cadian Capital Management LP boosted its position in SiBone by 96.8% during the fourth quarter. Cadian Capital Management LP now owns 1,171,100 shares of the company’s stock worth $23,094,000 after purchasing an additional 576,100 shares during the period. 98.11% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on SIBN shares. Truist Financial restated a “buy” rating and issued a $23.00 price target (up from $21.00) on shares of SiBone in a research report on Tuesday, August 4th. UBS Group increased their price target on SiBone from $24.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Weiss Ratings raised shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 20th. Finally, TD Cowen lifted their price objective on shares of SiBone from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.17.

Get Our Latest Report on SiBone

About SiBone

(Get Free Report)

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.

Recommended Stories